Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
HCWB
HCW Biologics Inc.
CAPPED RATING
HCW Biologics Inc. (HCWB) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (F).
Quantitative Factor Evaluation • Updated
Overall Rating
1.8
/ 5.0
D+
Value
B-
Factor Score
3.0
/ 5.0
Growth
F
Factor Score
0.2
/ 5.0
Profitability
C+
Factor Score
2.6
/ 5.0
Momentum
D-
Factor Score
0.8
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-1.6
EV / EBITDA
-1.3
Rev Growth YoY
N/M
Gross Margin
95.9%
Price Return 3M
-70.6%
Price Return 12M
-95.3%
Catalyst Signal
0.00
Market Cap
$1.9M
TTM Revenue
$6.7M
Price / Sales
0.3
ROE
-151.4%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B- (3.0) | F (0.2) | C+ (2.6) | D- (0.8) | C+ (2.6) | D+ (1.8) |
| 2026-11-05 | B- (3.0) | F (0.3) | C+ (2.6) | D- (1.0) | C+ (2.7) | C- (1.9) |
| 2026-10-29 | B- (3.0) | F (0.3) | C+ (2.6) | D- (1.0) | C+ (2.7) | C- (1.9) |
| 2026-10-22 | B- (3.0) | F (0.3) | C+ (2.6) | D- (1.0) | C+ (2.6) | C- (1.9) |
| 2026-10-15 | B- (3.0) | F (0.2) | C+ (2.6) | D- (1.0) | C+ (2.6) | C- (1.9) |
Page
1
of
4